External Antiparasitic Vectra 3D. Pipettes for cats
Treatment and prevention of flea infestation (Ctenocephalides felis and Ctenocephalides canis). The treatment prevents infestation by fleas for one month. It also prevents the multiplication of fleas for three months after application by inhibiting the hatching of eggs (ovicidal activity) and by inhibiting the appearance of adults from eggs laid by adult fleas (larvicidal activity).
The veterinary drug can be used as part of the treatment strategy for allergic dermatitis to flea bite (DAPP).
It has acaricidal efficacy and persistent repellent against tick infestations (Rhipicephalus sanguineus and Ixodes ricinus for one month, and Dermacentor reticulatus for up to three weeks).
If ticks are present when the medication is applied, not all ticks may die in the first 48 hours, but they may die within the week. For the elimination of ticks, it is recommended to use an appropriate tick extraction device.
Provides persistent repellent activity. Prevents stings of sandflies (Phlebotomus perniciosus), mosquitoes (Culex pipiens, Aedes aegypti) and for one month after application. The treatment also provides persistent insecticidal activity for one month against mosquitoes (Aedes aegypti) and the stable fly (Stomoxys calcitrans).
Each 0.8ml pipette contains 44 mg of dinotefuran, 3.9 mg of pyriproxyfen and 317 mg of permethrin.
Excipients: N-octyl-2-pyrrilidone and N-methylpyrrilidone.
Target species: Cats.
Dosage and route of administration
Punctual dorsal attachment.
After a single administration the medicine will prevent the infestation for a month. The treatment can be repeated once a month.
Special precautions for use
The safety of this veterinary drug has not been studied in puppies under 7 weeks of age or dogs weighing less than 1.5 kg.
The contact of the veterinary medicinal product with the eyes of the dog should be avoided. It can not be excluded that after the treatment an isolated tick adhered. For this reason, the transmission of infectious diseases can not be completely excluded if the conditions are
The veterinary drug remains effective when treated animals are immersed in water (for example when swimming or during bathing). Immersion in water, repeated weekly for a month and starting 48 hours after treatment, as well as washing with shampoo 2 weeks after treatment, do not affect the effectiveness of this medication. However, in the case of frequent washing with shampoo, or bathing within 48 hours after treatment, the duration of activity may be reduced.
Specific precautions to be taken by the person administering the veterinary medicinal product to the animals.
Do not eat, drink or smoke while handling the veterinary medicinal product.
Wash hands thoroughly immediately after use.
This veterinary medicine is irritating to the eyes and the skin.
Avoid contact of the medicine with the skin.
In case of accidental splashing on the skin, wash immediately with soap and water.
If the veterinary medicinal product accidentally comes in contact with the eyes, wash them with plenty of water.
If irritation persists in the eyes or on the skin, or if the medicine is accidentally swallowed, seek medical advice immediately and show the package leaflet or label.
People with known hypersensitivity to any of the ingredients should avoid contact with the veterinary medicinal product.
Children should not come into contact with treated dogs for at least four hours after administration of the medication. Therefore it is recommended to treat dogs in the afternoon, or before taking them for a walk. On the day of treatment, dogs should not be allowed to sleep together with their owners, especially with children. The applicators used should be removed immediately and should not be left visible or within the reach of children.
Wait until the area of application is dry before allowing the treated dog to come in contact with tissues or furniture.
On very rare occasions transient erythema, pruritus or signs of discomfort have been observed in the area of
application, which normally disappear spontaneously in the 24 hours following the administration of the drug.
On very rare occasions, gastrointestinal symptoms such as vomiting and diarrhea have been observed.
On very rare occasions, transient cosmetic effects (moist appearance, bristly hair, crowding) have been observed in the area of application, which is normally no longer observed after 48 hours.
The frequency of adverse reactions is classified according to the following groups:
- very frequently (more than 1 animal per 10 presents adverse reactions during a treatment)
- frequently (more than 1 but less than 10 animals per 100)
- infrequently (more than 1 but less than 10 animals per 1,000)
- on rare occasions (more than 1 but less than 10 animals per 10,000)
- very rarely (less than 1 animal per 10,000, including isolated cases).
Use during pregnancy, lactation or lay
The safety of the veterinary medicinal product in bitches during pregnancy and lactation has not been studied. The use of the veterinary medicinal product in pregnant or lactating dogs or in dogs intended for reproduction should be based on the benefit / risk assessment carried out by the responsible veterinarian.
The laboratory studies carried out with each of the components, dinotefuran, piriproxifen or permethrin, in rats and rabbits, have not shown teratogenic effects, toxic to the fetus, or toxic to the mother.
It has been seen that dinotefuran crosses the blood-milk barrier and is excreted in milk.
It has been found that N-methylpyrrolidone, one of the excipients of the veterinary drug, is teratogenic in laboratory animals.
(*) To pay with PayPal, Contrareembolso and Income/Bank Transfer minimum order will be 49€.
Ceva Santé Animale has been the company's fastest growing animal health in its first 10 years.
This puts us in ninth place worldwide in animal health, and the company was founded a few years ago, in 1999. Our expertise is in the fields of pharmacy and biology, where we have dedicated teams that aim to meet the specific demands of livestock, poultry, swine and pets. We continually strive to find better solutions for both existing and emerging diseases, which in turn improve animal health and productivity.
Our work goes beyond animal health. Today, a staggering 75% of all emerging human infectious diseases are of animal origin. Ceva is involved in combating the spread of infectious diseases that can be transmitted from wild or domestic animals and birds to humans, known as zoonosis diseases, including avian flu, brucellosis and Q-fever.
Ceva is in favor of contributing to the welfare and social programs worldwide. Our work ranges from research, development, production and supply of animal health products to the poorest livestock owners in the world, of which our SOS (Stamp Out Sleeping sickness) in Uganda is a good example, or the donation in the UK Canine Associations of Adaptil to make life less stressful for the dogs.
CEVA combines profitability with long-term growth.
Our work is divided into six major regions: Western Europe, Eastern Europe and Central (Turkey incl.), North America, Latin America, Africa / Middle East and Asia / Pacific.
We are present in 42 countries, where we work in more than 110 countries. We have 113 R & D centers, 21 production centers and over 3500 employees worldwide.
Leave us a message